Report Detail
Global GLP-1RA-based Therapy for Obesity Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4767531 |
- 29 October, 2026 |
- Global |
- 76 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global GLP-1RA-based Therapy for Obesity market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
GLP-1-based therapy has emerged as a promising approach in the management of obesity due to its dual effects on appetite control and weight regulation.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs),such as liraglutide and semaglutide,have been repurposed and approved for treating obesity in addition to diabetes.
This report is a detailed and comprehensive analysis for global GLP-1RA-based Therapy for Obesity market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GLP-1RA-based Therapy for Obesity market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global GLP-1RA-based Therapy for Obesity market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global GLP-1RA-based Therapy for Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global GLP-1RA-based Therapy for Obesity market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1RA-based Therapy for Obesity
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1RA-based Therapy for Obesity market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Shanghai Renhui Biopharmaceutical, Huadong Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
GLP-1RA-based Therapy for Obesity market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Semaglutide
Liraglutide
Tirzepatide
Beinaglutide
Other
Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Major players covered
Novo Nordisk
Eli Lilly
Shanghai Renhui Biopharmaceutical
Huadong Medicine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GLP-1RA-based Therapy for Obesity product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GLP-1RA-based Therapy for Obesity, with price, sales quantity, revenue, and global market share of GLP-1RA-based Therapy for Obesity from 2021 to 2026.
Chapter 3, the GLP-1RA-based Therapy for Obesity competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GLP-1RA-based Therapy for Obesity breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and GLP-1RA-based Therapy for Obesity market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1RA-based Therapy for Obesity.
Chapter 14 and 15, to describe GLP-1RA-based Therapy for Obesity sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global GLP-1RA-based Therapy for Obesity Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Semaglutide
- 1.3.3 Liraglutide
- 1.3.4 Tirzepatide
- 1.3.5 Beinaglutide
- 1.3.6 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global GLP-1RA-based Therapy for Obesity Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital and Clinic
- 1.4.3 Retail Pharmacies
- 1.4.4 Other
- 1.5 Global GLP-1RA-based Therapy for Obesity Market Size & Forecast
- 1.5.1 Global GLP-1RA-based Therapy for Obesity Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global GLP-1RA-based Therapy for Obesity Sales Quantity (2021-2032)
- 1.5.3 Global GLP-1RA-based Therapy for Obesity Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Novo Nordisk
- 2.1.1 Novo Nordisk Details
- 2.1.2 Novo Nordisk Major Business
- 2.1.3 Novo Nordisk GLP-1RA-based Therapy for Obesity Product and Services
- 2.1.4 Novo Nordisk GLP-1RA-based Therapy for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novo Nordisk Recent Developments/Updates
- 2.2 Eli Lilly
- 2.2.1 Eli Lilly Details
- 2.2.2 Eli Lilly Major Business
- 2.2.3 Eli Lilly GLP-1RA-based Therapy for Obesity Product and Services
- 2.2.4 Eli Lilly GLP-1RA-based Therapy for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Eli Lilly Recent Developments/Updates
- 2.3 Shanghai Renhui Biopharmaceutical
- 2.3.1 Shanghai Renhui Biopharmaceutical Details
- 2.3.2 Shanghai Renhui Biopharmaceutical Major Business
- 2.3.3 Shanghai Renhui Biopharmaceutical GLP-1RA-based Therapy for Obesity Product and Services
- 2.3.4 Shanghai Renhui Biopharmaceutical GLP-1RA-based Therapy for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Shanghai Renhui Biopharmaceutical Recent Developments/Updates
- 2.4 Huadong Medicine
- 2.4.1 Huadong Medicine Details
- 2.4.2 Huadong Medicine Major Business
- 2.4.3 Huadong Medicine GLP-1RA-based Therapy for Obesity Product and Services
- 2.4.4 Huadong Medicine GLP-1RA-based Therapy for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Huadong Medicine Recent Developments/Updates
3 Competitive Environment: GLP-1RA-based Therapy for Obesity by Manufacturer
- 3.1 Global GLP-1RA-based Therapy for Obesity Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global GLP-1RA-based Therapy for Obesity Revenue by Manufacturer (2021-2026)
- 3.3 Global GLP-1RA-based Therapy for Obesity Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of GLP-1RA-based Therapy for Obesity by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 GLP-1RA-based Therapy for Obesity Manufacturer Market Share in 2025
- 3.4.3 Top 6 GLP-1RA-based Therapy for Obesity Manufacturer Market Share in 2025
- 3.5 GLP-1RA-based Therapy for Obesity Market: Overall Company Footprint Analysis
- 3.5.1 GLP-1RA-based Therapy for Obesity Market: Region Footprint
- 3.5.2 GLP-1RA-based Therapy for Obesity Market: Company Product Type Footprint
- 3.5.3 GLP-1RA-based Therapy for Obesity Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global GLP-1RA-based Therapy for Obesity Market Size by Region
- 4.1.1 Global GLP-1RA-based Therapy for Obesity Sales Quantity by Region (2021-2032)
- 4.1.2 Global GLP-1RA-based Therapy for Obesity Consumption Value by Region (2021-2032)
- 4.1.3 Global GLP-1RA-based Therapy for Obesity Average Price by Region (2021-2032)
- 4.2 North America GLP-1RA-based Therapy for Obesity Consumption Value (2021-2032)
- 4.3 Europe GLP-1RA-based Therapy for Obesity Consumption Value (2021-2032)
- 4.4 Asia-Pacific GLP-1RA-based Therapy for Obesity Consumption Value (2021-2032)
- 4.5 South America GLP-1RA-based Therapy for Obesity Consumption Value (2021-2032)
- 4.6 Middle East & Africa GLP-1RA-based Therapy for Obesity Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 5.2 Global GLP-1RA-based Therapy for Obesity Consumption Value by Type (2021-2032)
- 5.3 Global GLP-1RA-based Therapy for Obesity Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 6.2 Global GLP-1RA-based Therapy for Obesity Consumption Value by Application (2021-2032)
- 6.3 Global GLP-1RA-based Therapy for Obesity Average Price by Application (2021-2032)
7 North America
- 7.1 North America GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 7.2 North America GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 7.3 North America GLP-1RA-based Therapy for Obesity Market Size by Country
- 7.3.1 North America GLP-1RA-based Therapy for Obesity Sales Quantity by Country (2021-2032)
- 7.3.2 North America GLP-1RA-based Therapy for Obesity Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 8.2 Europe GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 8.3 Europe GLP-1RA-based Therapy for Obesity Market Size by Country
- 8.3.1 Europe GLP-1RA-based Therapy for Obesity Sales Quantity by Country (2021-2032)
- 8.3.2 Europe GLP-1RA-based Therapy for Obesity Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific GLP-1RA-based Therapy for Obesity Market Size by Region
- 9.3.1 Asia-Pacific GLP-1RA-based Therapy for Obesity Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific GLP-1RA-based Therapy for Obesity Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 10.2 South America GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 10.3 South America GLP-1RA-based Therapy for Obesity Market Size by Country
- 10.3.1 South America GLP-1RA-based Therapy for Obesity Sales Quantity by Country (2021-2032)
- 10.3.2 South America GLP-1RA-based Therapy for Obesity Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa GLP-1RA-based Therapy for Obesity Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa GLP-1RA-based Therapy for Obesity Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa GLP-1RA-based Therapy for Obesity Market Size by Country
- 11.3.1 Middle East & Africa GLP-1RA-based Therapy for Obesity Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa GLP-1RA-based Therapy for Obesity Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 GLP-1RA-based Therapy for Obesity Market Drivers
- 12.2 GLP-1RA-based Therapy for Obesity Market Restraints
- 12.3 GLP-1RA-based Therapy for Obesity Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of GLP-1RA-based Therapy for Obesity and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of GLP-1RA-based Therapy for Obesity
- 13.3 GLP-1RA-based Therapy for Obesity Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 GLP-1RA-based Therapy for Obesity Typical Distributors
- 14.3 GLP-1RA-based Therapy for Obesity Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on GLP-1RA-based Therapy for Obesity. Industry analysis & Market Report on GLP-1RA-based Therapy for Obesity is a syndicated market report, published as Global GLP-1RA-based Therapy for Obesity Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of GLP-1RA-based Therapy for Obesity market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
